AAA
CBAY

Affinity Asset Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Affinity Asset Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,090,441
Closed -$25.8M – 118
2023
Q4 		$25.8M Sell
1,090,441
-38,935
-3% -$693K 4.7% 3
2023
Q3 		$16.8M Buy
1,129,376
+79,258
+8% +$1.05M 4.74% 3
2023
Q2 		$11.5M Sell
1,050,118
-33,000
-3% -$307K 4.02% 8
2023
Q1 		$9.44M Sell
1,083,118
-60,413
-5% -$484K 3.12% 7
2022
Q4 		$7.17M Sell
1,143,531
-146,980
-11% -$559K 2.81% 12
2022
Q3 		$4.52M Sell
1,290,511
-81,733
-6% -$294K 1.26% 23
2022
Q2 		$4.05M Buy
1,372,244
+100,000
+8% +$239K 1.71% 25
2022
Q1 		$3.96M Buy
1,272,244
+150,000
+13% +$472K 0.63% 28
2021
Q4 		$3.79M Buy
+1,122,244
New +$4.26M 1.38% 31

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Affinity Asset Advisors's CBAY Position: Q1 2024 in Review

Affinity Asset Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,090,441 shares — an estimated $25.8M sold.

Affinity Asset Advisors first reported a position in CBAY in Q4 2021 and held it in 9 quarters. The position peaked at $25.8M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Affinity Asset Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 1,090,441 Cymabay Therapeutics shares in Q1 2024, an estimated $25.8M.
  • Affinity Asset Advisors first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 9 quarters.
  • Affinity Asset Advisors's Cymabay Therapeutics position peaked at $25.8M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.